Royal Bank Of Canada Lantern Pharma Inc. Transaction History

Royal Bank Of Canada

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.91 - $9.51 $5,520 - $13,428	1,412 Added 17650.0%	1,420 $6,000
Q1 2024 Nov 05, 2024	SELL	$3.73 - $10.65 $5,266 - $15,037	-1,412 Reduced 99.44%	8 $0
Q1 2024 May 15, 2024	SELL	$3.73 - $10.65 $290 - $830	-78 Reduced 90.7%	8 $0
Q4 2023 Feb 14, 2024	SELL	$2.48 - $4.39 $49 - $87	-20 Reduced 18.87%	86 $0
Q3 2023 Nov 14, 2023	SELL	$3.41 - $5.51 $341 - $551	-100 Reduced 48.54%	106 $0
Q2 2023 Aug 14, 2023	BUY	$4.56 - $6.02 $939 - $1,240	206 New	206 $1,000
Q3 2022 Nov 14, 2022	SELL	$4.59 - $6.5 $206 - $292	-45 Reduced 34.09%	87 $0
Q2 2022 Aug 15, 2022	SELL	$4.82 - $7.45 $5,581 - $8,627	-1,158 Reduced 89.77%	132 $1,000
Q1 2022 May 16, 2022	BUY	$5.6 - $8.22 $7,089 - $10,406	1,266 Added 5275.0%	1,290 $9,000
Q4 2021 Feb 14, 2022	BUY	$7.11 - $11.04 $170 - $264	24 New	24 $0
Q3 2021 Nov 15, 2021	SELL	$10.53 - $14.93 $136 - $194	-13 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$12.94 - $19.89 $168 - $258	13 New	13 $0

1.31M

39.8K

6.1K

Ticker LTRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,830,900
Market Cap $37M
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.